New combo pill shows promise for blood sugar control in type 2 diabetes
NCT ID NCT00974090
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tested a new drug called MP-513 (Teneligliptin) combined with a standard diabetes medicine (sulfonylurea) in 194 Japanese adults with type 2 diabetes. The goal was to see if the combination safely lowers blood sugar levels over 12 weeks, with an extension up to 52 weeks. Participants had to be between 20 and 75 years old, on a diabetes diet and exercise plan, and already taking sulfonylurea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sapporo, Hokkaido, Japan
Conditions
Explore the condition pages connected to this study.